everolimus ratiopharm 5 mg tabletti
ratiopharm gmbh - everolimuusi - tabletti - 5 mg - everolimuusi
everolimus ratiopharm 10 mg tabletti
ratiopharm gmbh - everolimuusi - tabletti - 10 mg - everolimuusi
zessly
sandoz gmbh - infliksimabi - arthritis, psoriatic; psoriasis; crohn disease; arthritis, rheumatoid; colitis, ulcerative; spondylitis, ankylosing - immunosuppressantit - nivelreuman, crohnin tauti, haavainen paksusuolitulehdus, selkärankareuma, nivelpsoriaasi ja psoriaasi.
everolimus mylan 2.5 mg tabletti
mylan ab - everolimuusi - tabletti - 2.5 mg - everolimuusi
everolimus mylan 5 mg tabletti
mylan ab - everolimuusi - tabletti - 5 mg - everolimuusi
everolimus mylan 10 mg tabletti
mylan ab - everolimuusi - tabletti - 10 mg - everolimuusi
everolimus ethypharm 10 mg tabletti
ethypharm - everolimuusi - tabletti - 10 mg - everolimuusi
everolimus ethypharm 5 mg tabletti
ethypharm - everolimuusi - tabletti - 5 mg - everolimuusi
everolimus ethypharm 2.5 mg tabletti
ethypharm - everolimuusi - tabletti - 2.5 mg - everolimuusi
cimzia
ucb pharma sa - sertolitsumabipegoli - crohnin tauti - immunosuppressantit - cimzia, in combination with methotrexate (mtx), is indicated for the treatment of moderate to severe, active rheumatoid arthritis (ra) in adult patients when the response to disease-modifying antirheumatic drugs (dmard) including methotrexate, has been inadequate. cimzia voidaan antaa monoterapiana, jos potilas ei siedä metotreksaattia tai metotreksaattihoidon jatkaminen on sopimatonta. cimzia has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function, when given in combination with methotrexate.